HPV 16 is the most relevant oncogenic type in humans. Is the msot prevalent in all cancer sites involving HPV and affects both men and women.
Extraction from the ICO/IARC HPV information center data and additional literature review on the burden of HPV 16 in men and women with and without associated diseases.
HPV16 is detected in about 2.8% of women with a concomitant negative cervical cytology. There is a clear enrichment of HPV 16 when evaluation is done by abnormal results going from 19% in low garde lesions to 55% in invasive cervical cancer cases. Interestingly there is no major differences in these parameters by develop/developing world resgions. Information on genotype distribution in men with and without lesions is limited. Among HPV positive cases, HPV 16 is involved in over 80% of the cancer sites anal, vagina, vulva, penile and head and neck tumors.
Although a large body of published HPV genotype-specific data is currently available showing the relevance of HPV16 above all other HPV oncogenic types, data gaps remain for genotype-specific infection incidence and several world regions with the highest HPV cancer burden.